Similar articles

• Pregnancy and inflammatory bowel disease: a prospective case-control study.

  Malgarinos G, Gikas A, Delicha E, Stamataki A, Georgopoulos F, Papadimitriou A, Stanciu C, Triantafillidis JK. Malgarinos G, et al. Rev Med Chir Soc Med Nat Iasi. 2007 Jul-Sep;111(3):613-9. Rev Med Chir Soc Med Nat Iasi. 2007. PMID: 18293689
• Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD.

  Dulai PS, Siegel CA, Peyrin-Biroulet L. Dulai PS, et al. Gastroenterol Clin North Am. 2014 Sep;43(3):441-56. doi: 10.1016/j.gtc.2014.05.009. Epub 2014 Jun 16. Gastroenterol Clin North Am. 2014. PMID: 25110252 Review.
• Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: the first case in the literature.

  Sisman G, Erzin Y, Bal K. Sisman G, et al. J Crohns Colitis. 2013 Oct;7(9):e397-8. doi: 10.1016/j.crohns.2013.03.003. Epub 2013 Apr 10. J Crohns Colitis. 2013. PMID: 23583098 No abstract available.
• Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study.

  Yamamoto T, Umegae S, Matsumoto K. Yamamoto T, et al. Inflamm Bowel Dis. 2009 Oct;15(10):1460-6. doi: 10.1002/ibd.20915. Inflamm Bowel Dis. 2009. PMID: 19266566 Clinical Trial.
• New strategies in the management of inflammatory bowel disease.

  Rutgeerts P, Baert F. Rutgeerts P, et al. Acta Clin Belg. 1999 Oct;54(5):274-80. doi: 10.1080/17843286.1999.11754245. Acta Clin Belg. 1999. PMID: 10555385 Review.